Medication Policy Manual. Date of Origin: April 13, Topic: Testosterone cypionate, testosterone enanthate
|
|
- Esmond Thomas
- 8 years ago
- Views:
Transcription
1 Medication Policy Manual Topic: Testosterone cypionate, testosterone enanthate Policy No: dru395 Date of Origin: April 13, 2015 Committee Approval Date: December 11, 2015 Next Review Date: April 2016 Effective Date: January 1, 2016 IMPORTANT REMINDER This Medication Policy has been developed through consideration of medical necessity, generally accepted standards of medical practice, and review of medical literature and government approval status. Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. The purpose of medication policy is to provide a guide to coverage. Medication Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Description Testosterone replacement therapy (TRT) products are used in the treatment of hypogonadism (testosterone deficiency). The effectiveness of TRT is monitored by assessing serum testosterone levels, as well as improvement in sexual function, mood, fatigue, bone mineral density, and well-being. Dru395.2 Page 1 of 9
2 Policy/Criteria I. Most contracts require prior authorization approval of testosterone cypionate and testosterone enanthate prior to coverage. Testosterone cypionate and testosterone enanthate may be considered medically necessary when criteria A, B, C, or D below are met. A. A diagnosis of primary (Testicular) hypogonadism or secondary (Pituitary-Hypothalamic) hypogonadism caused by a condition listed in appendix 3 when documentation of at least two low testosterone levels (less than 300 ng/dl for total testosterone, or less than 9 ng/dl for free testosterone) drawn prior to 10 AM on two separate days is provided. OR B. As a continuous therapy for gender dysphoria when all of the following criteria are met: a. Clinical records document that the patient has the capacity to make fully informed decisions and consent for treatment. AND b. A licensed behavioral health practitioner has diagnosed gender dysphoria as defined by the DSM-5 criteria. AND c. At least one of the following criteria must be met for a period of 3 or more months prior to the initiation of hormone therapy i. Documentation of living as the desired gender; and/or ii. Psychotherapy with a licensed behavioral practitioner. OR C. To induce puberty in males with delayed puberty. OR D. Used secondarily in women with inoperable, metastatic breast cancer who are 1 to 5 years postmenopausal (testosterone enanthate only). II. Administration and Authorization Period A. OmedaRx considers testosterone cypionate and testosterone enanthate to be selfadministered medications or provider-administered products. B. Authorization shall be reviewed in the timeframes defined below: 1. Primary (Testicular) hypogonadism/secondary (Pituitary- Hypothalamic) hypogonadism: Authorization shall be reviewed after 6 months, and then at least annually to assure the testosterone level does not exceed 700 ng/dl (See Appendix 2, Lab Monitoring Guidelines for TRT Products). For patients with a testosterone level exceeding 700 ng/dl, ongoing coverage of testosterone replacement therapy will be authorized only when there is clinical documentation that the TRT dose will be adjusted for a goal level of less than 700 ng/dl. Dru395.2 Page 2 of 9
3 2. Gender reassignment therapy, induction of puberty, and metastatic breast cancer: authorization may be reviewed at least annually to confirm that current medical necessity criteria are met and that the medication is effective. III. Testosterone cypionate and testosterone enanthate are considered not medically necessary for the following: A. Age-related hypogonadism B. Low libido in women C. Weight gain in HIV-infected men Position Statement - Testosterone replacement therapy (TRT) is commonly used for treatment of hypogonadism in men and as part of gender reassignment therapy. All products are considered effective for increasing serum testosterone levels. [1] - There is no evidence demonstrating that any one TRT product is safer or more effective than less costly generic injectable options. There are no studies that directly compare the clinical effects of different TRT products. - Hypogonadism may be caused either by failure of the testicles to produce testosterone (primary), or by central defects in the hypothalamus or pituitary gland which lead to secondary testicular failure. - A diagnosis of hypogonadism is confirmed by measuring serum testosterone levels. [2] - Testosterone levels vary throughout the day and are highest in the morning. Normal ranges for serum testosterone levels are usually established using morning blood samples. [2] - Threshold testosterone levels below which adverse health symptoms occur are not known. Likewise, optimal levels of testosterone at which TRT improves outcomes are not known. For most symptoms in younger men, the average testosterone threshold corresponds to the lower limit of the normal range. [2] - Because testosterone levels vary significantly due to body rhythms, episodic secretion, and measurement variations, at least two levels should be obtained to confirm a diagnosis of hypogonadism. [2] - Normal ranges for testosterone vary among laboratories and assays. The Endocrine Society recommends that a lower limit for normal testosterone levels is 300 ng/dl for total testosterone and 9.0 ng/dl for free testosterone. [2] - The Endocrine Society Clinical Guideline recommends evaluating patients 3 to 6 months after initiating treatment to evaluate patients for side effects and to make sure total testosterone levels are between 400 ng/dl and 700 ng/dl. [2] - In March 2015, the FDA released a drug safety communication clarifying that the efficacy and safety of TRT have not been established for the treatment of low testosterone levels due to aging, even if a man s symptoms seem related to low Dru395.2 Page 3 of 9
4 testosterone. The communication also stated that there is a possible increased cardiovascular risk associated with testosterone use. [3] - Since the initial drug safety communication, a limitation of use has been added to the prescribing information for multiple testosterone replacement products. The updated labeling states that safety and efficacy has not been established for age-related hypogonadism (also referred to as late-onset hypogonadism). - Primary or Secondary hypogonadism not otherwise specified (NOS), including agerelated hypogonadism, is not a covered indication. For hypogonadism, testosterone replacement may be considered medically necessary when low testosterone levels are due to a documented medical cause as listed in Appendix 3. - Low-dose testosterone therapy is a standard treatment option for the management of delayed puberty in boys. Goals of therapy include the induction of secondary sexual characteristics or growth and the mitigation of psychosocial difficulties. [4] - Testosterone enanthate may be used secondarily in women with advancing inoperable metastatic breast cancer who are one to five years postmenopausal. Although testosterone enanthate is FDA-approved for this indication, newer, targeted therapies have largely replaced its use in this setting. [5] - Overall, TRT products are well tolerated. - TRT should not be started in men who are at high risk for, or who have, prostate cancer. Clinical Efficacy No single testosterone replacement therapy (TRT) product has been proven in reliable clinical studies to be more effective than another TRT product. - All TRT products appear to be similarly effective based on pharmacokinetic data. There is pharmacokinetic evidence that all topical testosterone products replete testosterone levels in men with hypogonadism. [6-16] - The FDA accepts open-label, non-comparative trials of new TRT formulations as sufficient to provide evidence of safety and efficacy. More clinically relevant endpoints would be trials with validated disease outcome measures, showing meaningful improvements in symptoms, such as low mood, sexual function, lean muscle mass, and energy levels. [1] - There are no trials comparing any branded TRT formulation, therefore there is no evidence that one branded TRT product is superior to another. - Long-term health outcomes of TRT, such as decreased incidence of fracture or cardiovascular risk, are uncertain. [1,3] - Clinical guidelines recognize TRT as standard of care and effective for treatment of hypogonadism in men. All products are considered effective in raising testosterone levels. Choice of TRT product is based on pharmacokinetics, patient preference, and cost. However, oral TRT is not recommended due to poor absorption and liver toxicity. [9,10] - The efficacy of TRT has not been established in men with age-related hypogonadism. [17] - There are no valid, reliable, clinically relevant endpoints for studies assessing the effect of testosterone on desire, frequency of sexual activity, erectile function, mood, energy, Dru395.2 Page 4 of 9
5 overall quality of life, body composition (lean and fat body mass), and bone mineral density in men with age-related hypogonadism. [1] Safety [6-16] - Overall, TRT is well tolerated. Common adverse effects ( 3%) include acne, gynecomastia, oral irritation (buccal formulation), headache, and enlarged prostate. [1] - TRT may be associated with increased risk of adverse cardiovascular outcomes (increased mortality, myocardial infarction, and stroke). Although findings in several large observational studies and meta-analyses are inconsistent, the FDA s Bone, Reproductive and Urologic Drugs Advisory Committee concluded that there is a small signal of risk. Based on these conclusions, the FDA subsequently released a drug safety communication related to the CV risk and has required labeling changes for all prescription testosterone products. [1,3,18-20] - TRT is contraindicated in men with known or suspected prostate cancer. - In 2009, the FDA issued a MedWatch safety alert of inadvertent (secondary) testosterone exposure with topical testosterone gel (Testim and AndroGel), based on eight case reports of exposure in children, age nine months to five years old. Signs of virilization (development of male secondary sexual characteristics) and bone aging were observed. Black box warnings are now required on all topical gel and solution formulations of testosterone, as well as educational REMS programs to reduce secondary exposure. [21] Appendix 1: Branded Testosterone Replacement Therapy (TRT) Products Topical testosterone topical solution 2% (Axiron ) testosterone topical gel 1% and 1.62% (AndroGel and AndroGel Pump ) testosterone topical gel 2% (Fortesta ) testosterone topical gel 1% (Testim Gel ) testosterone topical gel 1% (Vogelxo ) testosterone transdermal patch 2-4 mg/24 hours (Androderm ) Oral/Buccal methyltestosterone 10 mg capsule (Android, Testred ) methyltestosterone 10 mg capsule (Methitest ) testosterone 30 mg extended-release buccal tablets (Striant ) Injectable testosterone undecanoate injection (Aveed ) Dru395.2 Page 5 of 9
6 Appendix 1: Branded Testosterone Replacement Therapy (TRT) Products Nasal gel testosterone nasal gel 4.5% (Natesto ) Subcutaneous Pellet testosterone pellets 75 mg (Testopel ) Appendix 2: Lab Monitoring Guidelines for TRT Products Transdermal patches Androderm Measure morning testosterone (following application of the patch the previous evening) Transdermal gels and solutions AndroGel, AndroGel Pump, Testim Fortesta Axiron Vogelxo Measure pre-dose morning testosterone level Measure testosterone 2 hours after application Measure testosterone 2 to 8 hours after application Measure testosterone 4 to 8 hours after application Subcutaneous pellet Testopel Measure pre-dose level and periodically during therapy Buccal tablet Striant Measure pre-dose morning testosterone level Nasal gel Natesto Measure pre-dose level Injectable Aveed testosterone cypionate (generics) testosterone enanthate (generics) Measure pre-dose level and periodically during therapy Measure pre-dose level and periodically during therapy Measure pre-dose level and periodically during therapy Dru395.2 Page 6 of 9
7 Appendix 3: Causes of Primary (Testicular) and Secondary (Pituitary-Hypothalamic) hypogonadism Primary (Testicular) Hypogonadism due to testicular dysfunction, including but not limited to the following conditions: a Bilateral Torsion Cryptorchidism Disorders of androgen biosynthesis Klinefelter s syndrome or other chromosomal abnormalities Myotonic dystrophy Orchitis Toxic damage from chemotherapy, alcohol, or heavy metals Trauma to the testicles Vanishing testis syndrome Varicocele Secondary (Pituitary-Hypothalamic) hypogonadism due to pituitary-hypothalamic dysfunction, including but not limited to the following conditions Congenital GnRH deficiency Hyperprolactinemia Idiopathic gonadotropic or luteinizing hormone-releasing hormone deficiency Kallman Syndrome Pituitary-hypothalamic dysfunction (not otherwise specified) Pituitary-hypothalamic injury from tumors, trauma, or radiation a Primary (Testicular) or Secondary (Pituitary-Hypothalamic) Hypogonadism (not otherwise specified, including age-related) is not a covered indication. Dru395.2 Page 7 of 9
8 Cross References Testosterone Replacement Therapies, BlueCross BlueShield Association Medical Policy, , Issue 12:2014 Transgender Services, Medical Policy. Medicine, Policy No Preferred transdermal testosterone replacement therapy products (AndroGel, AndroGel Pump ), Medication Policy Manual, Policy No. dru411 Non-preferred transdermal testosterone products, Medication Policy Manual, Policy No. dru415 Non-preferred testosterone replacement products, Medication Policy Manual, Policy No. dru297 Codes Number Description HCPCS J1070 testosterone cypionate, 100mg HCPCS J1071 testosterone cypionate, 1mg HCPCS J1080 testosterone cypionate, 200mg HCPCS J3120 testosterone enanthate, 100 MG HCPCS J3121 testosterone enanthate, 1mg HCPCS J3130 testosterone enanthate, 100 MG References 1. U.S. Food and Drug Administration. FDA Briefing Information for the September 17, 2014 Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting. [cited 11/7/2014]; Available from: roductivehealthdrugsadvisorycommittee/ucm pdf. 2. Bhasin, S, Cunningham, GR, Hayes, FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 2010;95: PMID: U.S. Food and Drug Administration. Summary Minutes of the Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. [cited 11/7/2014]; Available from: roductivehealthdrugsadvisorycommittee/ucm pdf. 4. Palmert, MR, Dunkel, L. Clinical practice. Delayed puberty. The New England journal of medicine Feb 2;366(5): PMID: Ellis, M, Naughton, MJ, Ma, CX. Treatment approach to metastatic hormone receptorpositive breast cancer: Endocrine therapy. In: UpToDate, Basow, DS (Ed). UpToDate, Waltham, MA, Androderm [package insert]. Parsippany, NJ: Watson Pharma; April Androgel 1% [package insert]. North Chicago, IL: Abbvie; November Androgel 1.62% [package insert]. North Chicago, IL: Abbvie; November Aveed [package insert]. Malvern, PA: Endo Pharmaceuticals; September Axiron [package insert]. Indianapolis, IN: Eli Lilly and Company; June 2014 Dru395.2 Page 8 of 9
9 11. Fortesta [package insert]. Malvern, PA: Endo Pharmaceuticals; June Natesto [package insert]. Malvern, PA: Endo Pharmaceuticals; November Testim [package insert]. Chesterbrook, PA: Auxilium Pharmaceuticals; June Testopel [package insert]. Chesterbrook, PA: Auxilium Pharmaceuticals; January Vogelxo [package insert]. Maple Grove, MN: Upsher-Smith Laboratories; June Striant [package insert]. Chesterbrook, PA: Actient Pharmaceuticals; June Testosterone Products: Drug Safety Communication - FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack And Stroke. [cited 2015]; Available from: ucts/ucm htm 18. Vigen, R, O'Donnell, CI, Baron, AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. United States, p Xu, L, Freeman, G, Cowling, BJ, Schooling, CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108. PMID: Finkle, WD, Greenland, S, Ridgeway, GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. United States, p. e MedWatch. FDA news release: Testosterone Gel Safety Concerns Prompt FDA to Require Label Changes, Medication Guide. 7May2009. [cited 2/16/2011]; Available from: Revision Date Revision Summary 12/11/2015 Clarified that the cause of hypogonadism must be caused by a condition listed in appendix 3 Allowed for reauthorization if testosterone levels exceed 700 ng/ml. Reauthorization requires a documented plan to address the high level or adjust the dose. Updated appendix 3 with additional causes of hypogonadism Dru395.2 Page 9 of 9
Medication Policy Manual
Medication Policy Manual Topic: Non-preferred testosterone replacement therapy products (Androderm, Androgel, Aveed, Axiron, Fortesta, Natesto, Striant, Testim Gel, Testopel, Vogelxo, compounded testosterone
More informationCommittee Approval Date: October 14, 2014 Next Review Date: March 2015
Medication Policy Manual Topic: Testosterone replacement therapy products: - Androderm, - Axiron, - Fortesta, - Striant, - Testim Gel, - Natesto, - Vogelxo Policy No: dru297 Date of Origin: March 15, 2013
More informationA list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke
More informationTestosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS
Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS The faces of Low Testosterone What your patients are seeing Pharmacy Industry Testosterone
More informationTestosterone Treatment in Older Men
Testosterone Treatment in Older Men J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships to disclose.
More informationNDA 021015 LABELING SUPPLEMENT AND PMR REQUIRED REMS MODIFICATION NOTIFICATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021015 LABELING SUPPLEMENT AND PMR REQUIRED REMS MODIFICATION NOTIFICATION AbbVie, Inc. Attention: Gennadiy
More informationtestosterone_pellet_implantation_for_androgen_deficiency_in_men 10/2015 N/A 11/2016 10/2015 This policy is not effective until December 30, 2015
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency_in_men
More informationPDL Class: Topical Androgens
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Topical Androgens Month/Year of Review:
More informationX-Plain Low Testosterone Reference Summary
X-Plain Low Testosterone Reference Summary Introduction Testosterone is the most important male sex hormone. It helps the body produce and maintain adult male features. Low levels of testosterone affect
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM G.R. Dohle (chair), S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationt!k EUROPEAN MEDICINES AGENCY TESTOSTERONE UPDATE
ACRUX (ACR) - ASX ANNOUNCEMENT 24 NOVEMBER 2014 EUROPEAN MEDICINES AGENCY TESTOSTERONE UPDATE The European Medicines Agency (EMA) released a statement regarding the use of Testosterone Replacement Therapy
More informationData Trends Report. Encuity. Testosterone Replacement Therapy
Encuity Data Trends Report Encuity has cost-effective solutions to suit your business needs through our various syndicated services. Encuity Data Trends Report provides insight on how our collective services
More informationFebruary 25, 2014. Dear Dr. Hamburg:
February 25, 2014 Margaret A. Hamburg, M.D. Commissioner Food and Drug Administration Department of Health and Human Services WO 2200 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 Division of
More informationTestosterone Replacement Therapy. Craig Ensign, MPAS, PA-C University of Utah School of Medicine Urology Division
Testosterone Replacement Therapy Craig Ensign, MPAS, PA-C University of Utah School of Medicine Urology Division Lecture Outline 1. Anatomy and physiology 2. Definition and etiology 3. Signs and symptoms
More informationNORTHWEST UROLOGICAL CLINIC, P.C. Physicians and Surgeons N W U C. Testosterone Replacement
N W U C Testosterone Replacement Low testosterone (low T) is a very common problem in men over 40, and sometimes even in men younger than 40. Men s testosterone levels usually peak in the early 20 s, then
More informationTestosterone, Growth Hormone and Bioidentical Hormones Prescription Issues
Testosterone, Growth Hormone and Bioidentical Hormones Prescription Issues T. Brooks Vaughan III, MD Department of Endocrinology UAB July 11, 2015 Brooks Vaughan, MD Associate Professor, Medicine, Pediatrics
More informationTESTOSTERONE The Future?
TESTOSTERONE The Future? Martin M. Miner MD Co-Director Men s Health Center The Miriam Hospital Clinical Professor of Family Medicine and Urology Warren Alpert School of Medicine of Brown University Providence,
More informationAcrux (ASX: ACR) 28 April 2014
Acrux (ASX: ACR) 28 April 2014 FORWARD-LOOKING STATEMENTS 2 This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown
More informationTestosterone in Old(er) Men
Testosterone in Old(er) Men Disclosure Information J. Bruce Redmon, M.D. Associate Professor Division of Endocrinology I have no financial relationships to disclose. I will not discuss off label use and/or
More informationUTAH MEDICAID DUR REPORT JUNE 2015 ANDROGENIC AGENTS: TESTOSTERONE (UPDATE)
UTAH MEDICAID DUR REPORT JUNE 2015 ANDROGENIC AGENTS: TESTOSTERONE (UPDATE) AVEED (testosterone undecanoate) intramuscular injection CIII Natesto (testosterone) nasal gel CIII VOGELXO (testosterone) topical
More informationPrevalence Diagnosis and Treatment of Hypogonadism in Primary Care Practice by Culley C. Carson III, MD, Boston University Medical Campus
Prevalence Diagnosis and Treatment of Hypogonadism in Primary Care Practice by Culley C. Carson III, MD, Boston University Medical Campus Hypogonadism is defined as deficient or absent male gonadal function
More informationHypogonadism and Testosterone Replacement in Men with HIV
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hypogonadism and Testosterone Replacement in Men with HIV Stephanie T. Page, MD, PhD Robert B. McMillen Professor in Lipid Research, Associate Professor of
More informationTESTOSTERONE REPLACEMENT THERAPY FOR THE AGING MALE: COUNSELING INSIGHTS FOR THE PHARMACIST TIM DRAKE, PHARM.D.
TESTOSTERONE REPLACEMENT THERAPY FOR THE AGING MALE: COUNSELING INSIGHTS FOR THE PHARMACIST TIM DRAKE, PHARM.D. TESTOSTERONE REPLACEMENT THERAPY FOR THE AGING MALE: COUNSELING INSIGHTS FOR THE PHARMACIST
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations subject to conditions and detailed explanation of the scientific grounds for the differences from
More informationMale New Patient Package
Male New Patient Package The contents of this package are your first step to restore your vitality. Please take time to read this carefully and answer all the questions as completely as possible. Thank
More informationTestosterone Replacement Therapies
Testosterone Replacement Therapies Policy Number: 5.01.23 Last Review: 7/2015 Origination: 7/2015 Next Review: 7/2016 Policy BCBSKC will provide coverage for testosterone replacement therapies when it
More informationSelling Low T Is Big Pharma Taking Big Risks with Patient Safety?
Selling Low T Is Big Pharma Taking Big Risks with Patient Safety? An Overview of the Testosterone Replacement Therapy Marketplace and Potential Risks to Consumers Prepared by the attorneys of the Charles
More informationTESTOSTERONE REPLACEMENT THERAPY: WHAT YOU NEED TO KNOW ABOUT IT
TESTOSTERONE REPLACEMENT THERAPY: WHAT YOU NEED TO KNOW ABOUT IT 1 As men get older, their doctors prescribe drugs to replace low testosterone levels in their bodies known as hypogonadism, or more commonly
More informationGARY S. DONOVITZ, M.D., F.A.C.O.G.
Sub-Cutaneous Hormone Pellet Therapy- The Comprehensive Treatment to Optimize and Balance Hormones Using the BioTE Method GARY S. DONOVITZ, M.D., F.A.C.O.G. The BioTE method of hormone replacement is a
More informationMale Patient Questionnaire & History
Male Patient Questionnaire & History Name: Today s Date: (Last) (First) (Middle) Date of Birth: Age: Occupation: Home Address: City: State: Zip: E- Mail Address: May we contact you via E- Mail? ( ) YES
More informationBIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
More informationContinuity Clinic Educational Didactic. December 8 th December 12 th
Continuity Clinic Educational Didactic December 8 th December 12 th MKSAP Question 1 A 60-year-old man is evaluated for a 1-year history of generalized fatigue and lack of energy. He has had erectile dysfunction
More informationTestosterone & Testosterone Replacement Therapy
your PR.i.VATES Testosterone & Testosterone Replacement Therapy www.yourprivates.org.uk CONTENTS TESTOSTERONE & TRT Contents Introduction 3 Purposes of testosterone 4 How will I be affected by an orchidectomy?
More informationSubcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.
Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationThe ABC s and T s of Male Infertility
The ABC s and T s of Male Infertility Men s Health Initiative of BC - Focus on Testosterone Ethan D. Grober, MD, MEd, FRCSC Assistant Professor University of Toronto Department of Surgery, Division of
More informationTreatment of Males with Low Testosterone
Treatment of Males with Low Testosterone Noridian Healthcare Solutions, LLC Close Jump to Section... Please Note: This is a Proposed LCD. Proposed LCDs are works in progress and not necessarily a reflection
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationHormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions
Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions IMPORTANCE OF HORMONE BALANCE Importance of Hormone Balance Help you live a long, healthy life Help you
More informationShalender Bhasin, MD. Glenn R Cunningham, MD. Mohit Khera, MD, MBA, MPH
Shalender Bhasin, MD Program Chair Professor of Medicine Boston University School of Medicine Section Chief Division of Endocrinology, Diabetes & Nutrition Boston, MA Glenn R Cunningham, MD Professor of
More informationTestosterone. Testosterone For Women
Testosterone Testosterone is a steroid hormone. Popular use of the term steroid leads people to believe that it signifies a drug that s illegal and abused by some body builders and other athletes. While
More informationTestosterone Therapy for Women
Testosterone Therapy for Women The Facts You Need Contents 2 INTRODUCTION: The Facts You Need... 3-4 CHAPTER 1: Testosterone and Women... 5-9 CHAPTER 2: Testosterone Therapy for Women... 10-14 CONCLUSION:
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationEffective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Implantable Hormone Replacement Pellets Policy #: 444 Latest
More informationTestosterone Testing
20, 2012 Health Technology Assessment Testosterone Testing Final Evidence Report February 6, 2015 Health Technology Assessment Program (HTA) Washington State Health Care Authority PO Box 42712 Olympia,
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Diagnosis and Assessment Module 2 2 Objectives Identify clinical manifestations and symptoms of hypogonadism Describe components of comprehensive
More informationHormone Replacement Therapy For Men Consultation Information. Round Rock Jollyville Westlake 512-231-1444 www.urologyteam.com.
Hormone Replacement Therapy For Men Consultation Information Round Rock Jollyville Westlake 512-231-1444 www.urologyteam.com Rev 05/13 Table of Contents Biological Aging and Hormones 2 As we age.... 3
More informationANDROGEN DEFICIENCY A GUIDE TO MALE HORMONES A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM
ANDROGEN DEFICIENCY A GUIDE TO MALE HORMONES A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM AT A GLANCE First published in July 2003 by Andrology Australia 4th Edition, December
More informationShira Miller, M.D. Los Angeles, CA 310-734-8864 www.shiramillermd.com. The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library
Shira Miller, M.D. Los Angeles, CA 310-734-8864 The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library 2 Outline What is hormone therapy? Why would healthy men and women need to think about
More informationAsk your healthcare provider about LONG-ACTING AVEED (testosterone undecanoate) AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR. Not an actual patient.
Ask your healthcare provider about LONG-ACTING AVEED (testosterone undecanoate) AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR AFTER THE FIRST MONTH OF THERAPY Not an actual patient. CONSUMERS What is the
More informationCONCORD INTERNAL MEDICINE TESTOSTERONE DEFICIENCY PROTOCOL
CONCORD INTERNAL MEDICINE TESTOSTERONE DEFICIENCY PROTOCOL Douglas G. Kelling, Jr., MD Carmella Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised April 29, 2012 The information contained in this
More informationto the cases and then talk about management. But really who hasn t had a patient come into the
JODIE REIDER, MD 1 So I m going to begin with just presenting a few cases and then at the end of the talk we ll go back to the cases and then talk about management. But really who hasn t had a patient
More informationFebruary 1, 2014 RESTORING STRENGTH AND VITALITY THROUGH HORMONES FACTS, FANTASIES, POSSIBILITIES, AND PITFALLS
February 1, 2014 RESTORING STRENGTH AND VITALITY THROUGH HORMONES FACTS, FANTASIES, POSSIBILITIES, AND PITFALLS Calvin Hirsch, MD Professor of Clinical Internal Medicine (Geriatrics) UC Davis School of
More information------------------------------ ------ ---------
INTERNAL MEDICINE CENTRE Male Patie nt Questionnaire & History Name: -;;-= c:;--:;- ---,=-,-,- Today's Date: lust) jflrsi) {Middle} Date of Birth: Age: Occupation: Home Address: City: State: Zip: ------------------------------
More informationManagement of Erectile Dysfunction and Cardiovascular Disease Princeton III Consensus Recommendations
Management of Erectile Dysfunction and Cardiovascular Disease Princeton III Consensus Recommendations Reptile Dysfunction This is a talk about sex, and contains potentially offensive images Men Avoid Doctors
More informationELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits
VI: 2 ELEMENTS FOR A PUBLIC SUMMARY Bicalutamide (CASODEX 1 ) is a hormonal therapy anticancer agent, used for the treatment of prostate cancer. Hormones are chemical messengers that help to control the
More informationFocus. Andropause: fact or fiction? Introduction. Johan Wilson is an Auckland GP KEY POINTS
1 of 5 Focus Andropause: fact or fiction? Johan Wilson is an Auckland GP Introduction Androgen deficiency in the ageing male, or andropause, is being diagnosed with increased frequency. A growing body
More informationMale Patient Questionnaire & History
Male Patient Questionnaire & History Name: Today s Date: (Last) (First) (Middle) Date of Birth: Age: Weight: Occupation: Home Address: City: State: Zip: Home Phone: Cell Phone: Work: E-Mail Address: May
More informationMedication Guide Testim (TĔS tim) CIII (testosterone gel)
Medication Guide Testim (TĔS tim) CIII (testosterone gel) Read this Medication Guide that comes with Testim before you start using it and each time you get a refill. There may be new information. This
More informationCONSIDERATIONS BEFORE TESTOSTERONE THERAPY WHAT S UP WITH THE T?
CONSIDERATIONS BEFORE TESTOSTERONE THERAPY WHAT S UP WITH THE T? Emily Wood Demetriou, MD MMP Endocrinology and Diabetes ACP Conference September 26, 2015 -29 yo man presents to your clinic for hypogonadism
More informationDefinitions. Androgen deficiency. Clinical Hypogonadism* Low serum testosterone level Also called biochemical hypogonadism
MALE HYPOGONADISM Mark Sigman Krishnamurthi Family Professor and Chief of Urology Warren Alpert Medical School of Brown University Chief of Urology Rhode Island and the Miriam Hospitals 1 Topics What is
More informationMale Health Issues. Survivorship Clinic
Male Health Issues The effects of cancer therapy on male reproductive function depend on many factors, including the boy s age at the time of cancer therapy, the specific type and location of the cancer,
More informationAbout Andropause (Testosterone Deficiency Syndrome)
About Andropause (Testosterone Deficiency Syndrome) There are many myths, misconceptions and a general lack of awareness about this easily treated hormonal imbalance that research shows affects 20% of
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationAVEED Billing and Coding Guide
AVEED Billing and Coding Guide 1-855-myAVEED (692-8333) INDICATIONS AND USAGE AVEED is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence
More informationTestosterone for women, who when and how much?
Medicine, Nursing and Health Sciences Testosterone for women, who when and how much? Susan R Davis MBBS FRACP PhD Women s Health Research Program School of Public Health Monash University Melbourne Medicine,
More informationMedication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010
Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationTUE Applications for Testosterone Physician Worksheet
TUE Applications for Testosterone Physician Worksheet **Attention Physicians** USADA will not process any Therapeutic Use Exemption for an athlete for the use of testosterone unless we receive all of the
More informationTestosterone deficiency: myth, facts, and controversy Martin Miner, MD, 1 Jack Barkin, MD, 2 Matt T. Rosenberg, MD 3 1
Testosterone deficiency: myth, facts, and controversy Martin Miner, MD, 1 Jack Barkin, MD, 2 Matt T. Rosenberg, MD 3 1 Departments of Family Medicine and Urology, Miriam Hospital, Brown University, Providence,
More informationForm ### Transgender Hormone Therapy - Estrogen Informed Consent SAMPLE
What are the different medications that can help to feminize me? Estrogen - Different types of the hormone estrogen can help you appear more feminine. Estrogen is the female sex hormone. Androgen blocker
More informationUnderstanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding
Controversies of testosterone replacement therapy in hypogonadal men with prostate cancer Samuel Deem, DO CULTURA CREATIVE (RF) / ALAMY Understanding the controversies surrounding testosterone replacement
More informationMedication Guide ANDROGEL (AN DROW JEL) CIII (testosterone gel) 1%
Medication Guide ANDROGEL (AN DROW JEL) CIII (testosterone gel) 1% Read this Medication Guide that comes with ANDROGEL 1% before you start taking it and each time you get a refill. There may be new information.
More informationMedication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
More informationTestosterone For Men. Information on the use of testosterone in males
Testosterone For Men Information on the use of testosterone in males Contents Testosterone Introduction 3 What is Testosterone? 4 Causes of Testosterone Deficiency 5 How is Testosterone Deficiency in Men
More informationTalk to your doctor about low testosterone
Talk to your doctor about low testosterone Maybe he doesn t find me attractive any more? Maybe he needs to lose some weight? Maybe he s lost his spark? Bayer Pharma AG Müllerstraße 178 13353 Berlin Germany
More informationCOULD IT BE LOW TESTOSTERONE?
COULD IT BE LOW TESTOSTERONE? By Dr. Lauren M. Bramley For thousands of years women have been recognized for their sensitivity to hormones. PMS, post partum depression, menopause have long been plights
More informationTestosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
SPECIAL FEATURE Clinical Practice Guideline Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Shalender Bhasin, Glenn R. Cunningham, Frances
More informationAging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone
Aging Well - Part V Hormone Modulation -- Growth Hormone and Testosterone By: James L. Holly, MD (The Your Life Your Health article published in the December 4th Examiner was a first draft. It was sent
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationMedication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014
Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective
More informationNational Medical Policy
National Medical Policy Subject: Implantable Hormone Pellets Policy Number: NMP 507 Effective Date*: January 2012 Updated: July 2015 This National Medical Policy is subject to the terms in the IMPORTANT
More informationTestosterone Therapy in Adult Men with Androgen Deficiency Syndromes:
T h e E n d o c r i n e S o c i e t y s Clinical Guidelines Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Authors: Shalender Bhasin,
More informationLou Haenel, IV, DO Endocrinology October 3, 2015 TESTOSTERONE AND MALE HYPOGONADISM : DECIDING WHEN TO TREAT
Lou Haenel, IV, DO Endocrinology October 3, 2015 TESTOSTERONE AND MALE HYPOGONADISM : DECIDING WHEN TO TREAT Figure 1 The hypothalamic pituitary gonadal axis in men and the impact of testosterone therapy
More informationAndrogens and CVD. Brandon Orr- Walker April 2014
Androgens and CVD Brandon Orr- Walker April 2014 Agenda What is normal physiology of Aging? Hypogonadism and disease If some is good is more becer? CVD safety Clinical features of Androgen Deficiency
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationTestosterone Replacement Informed Consent. Patient Name: Date:
Testosterone Replacement Informed Consent Patient Name: Date: This form is designed to document that you understand the information regarding Testosterone Replacement Therapy, so that you can make an informed
More informationPromoting the Fountain of Youth: Low-T and Estrogen Deficiency
Promoting the Fountain of Youth: Low-T and Estrogen Deficiency Adriane Fugh-Berman MD Georgetown University Medical Center ajf29@georgetown.edu Hormone Therapy in Women Animal glandulars became popular
More informationThe Truth about Testosterone Therapy
Mid-South Men s Health September 2014 The Truth about Testosterone Therapy In this Issue, we will cover All Aspects of Testosterone Replacement Therapy, including the published studies and links. U.S.
More informationVitamin D. Sources of vitamin D
1 has been in the news frequently this past year, including an article in The New York Times on November 16, 2009. So what is this vitamin? Why is it important? Most people have heard that vitamin D is
More informationAXIRON (AXE-e-RON) CIII
Medication Guide 1 AXIRON (AXE-e-RON) CIII (testosterone) topical solution Read this Medication Guide before you start using AXIRON and each time you get a refill. There may be new information. This information
More informationJournal of Men s Health Editorial. Death by Testosterone?
Journal of Men s Health Editorial 2/20/14 Death by Testosterone? Martin Miner MD Co- Director Men s Health Center The Miriam Hospital Clinical Associate Professor of Family Medicine and Urology The Warren
More informationVaricocele: To Fix or Not to Fix? That is the Question. Edmund S. Sabanegh, MD
Varicocele: To Fix or Not to Fix? That is the Question. Edmund S. Sabanegh, MD Professor and Chairman, Department of Urology, Cleveland Clinic Lerner College of Medicine; Cleveland, Ohio Objectives: Review
More informationMale New Patient Package
Male New Patient Package The contents of this package are your first step to restore your vitality. Please take time to read this carefully and answer all the questions as completely as possible. Thank
More informationHormone Replacement Therapy For Women
Hormone Replacement Therapy For Women Bio-identical Hormone Replacement Therapy Gail Eberharter M.D. May 10, 2009 There are three main hormones that are responsible for the menstrual cycle, sexual drive
More informationLakeview Endocrinology and Diabetes Consultants. 2719 N Halsted St C-1. Chicago IL 60614 P: 773 388 5685 F: 773 388 5687. www.lakeviewendocrinolgy.
Lakeview Endocrinology and Diabetes Consultants 2719 N Halsted St C-1 Chicago IL 60614 P: 773 388 5685 F: 773 388 5687 www.lakeviewendocrinolgy.com Patient information: Early menopause (premature ovarian
More informationBio-Identical Hormone FAQ s
Bio-Identical Hormone FAQ s What are bio-identical hormones? They are derived from a natural plant source and professionally compounded to be biologically identical to human form of estradiol and testosterone.
More informationA novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function
Original Article TESTOSTERONE GEL NORMALIZES ANDROGEN LEVELS T.A. McNICHOLAS et al. Men s health has become so important that it is now virtually a political issue. With advancing age, testosterone levels
More informationPHARMACEUTICAL MANAGEMENT PROCEDURES
PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription
More information